Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis

Current Medical Research and Opinion

Volumn 20, Issue 5, 2004, Pages 757-764

  Harris, Steven T ^a   Watts, N B ^b   Li, Z ^c   Chines, A A ^c   Hanley, D A ^d   Brown, J P ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

Author keywords

Bone mineral density; Fractures; Once a week dosing; Postmenopausal osteoporosis; Risedronate

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM CARBONATE; RISEDRONIC ACID; TUMS; VITAMIN D;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NAUSEA; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE;

AGED; ANALYSIS OF VARIANCE; BONE DENSITY; DOUBLE-BLIND METHOD; ETIDRONIC ACID; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 2542441388     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003566     Document Type: Article

References (9)

1. National Osteoporosis Foundation, Washington, DC [online]. Available from http://www.nof.org/osteoporosis/index.htm. [Accessed August 2003]
2. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. J Am Med Assoc 1999;282:1344-52
3. Reginster J, Minnie HW, Sörensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2002;11:83-9
4. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344:333-40
5. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11
6. Watts NB, Lindsay R, Li Z, Kasibhatla C, Brown J. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003;14:437-41
7. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48
8. Watts NB, Lindsay R, Li Z, Brown J. Vertebral fracture risk reduction over two years with risedronate 35 mg once a week. Osteoporos Int 2002;3:S40
9. Gehan EA. The evaluation of therapies: historical control studies. Stat Med 1984;3:315-24